Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Total Non-Current Liabilities (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Total Non-Current Liabilities for 6 consecutive years, with -$344.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities fell 439.3% year-over-year to -$344.0 million, compared with a TTM value of -$344.0 million through Dec 2025, down 439.3%, and an annual FY2025 reading of -$344.0 million, down 439.3% over the prior year.
  • Total Non-Current Liabilities was -$344.0 million for Q4 2025 at Cytek Biosciences, down from $113.8 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $113.8 million in Q3 2025 and bottomed at -$382.0 million in Q1 2025.
  • Average Total Non-Current Liabilities over 5 years is $41.0 million, with a median of $92.8 million recorded in 2024.
  • The sharpest move saw Total Non-Current Liabilities soared 73.86% in 2022, then tumbled 491.29% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $56.7 million in 2021, then surged by 62.82% to $92.3 million in 2022, then grew by 7.17% to $99.0 million in 2023, then rose by 2.46% to $101.4 million in 2024, then plummeted by 439.3% to -$344.0 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for CTKB at -$344.0 million in Q4 2025, $113.8 million in Q3 2025, and $113.3 million in Q2 2025.